← Leaderboards
William A Weiss
University Of California, San Francisco
$31,543,847
Attributed
$56,136,598
Total exposure
27
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$56,136,598 · 27
By mechanism
R01$41,589,647 · 13
U01$6,311,561 · 2
P01$3,557,852 · 4
P50$1,748,724 · 1
R33$1,182,180 · 1
K02$608,850 · 1
Top collaborators
- Michael D. Taylor31 shared
- Robert J Wechsler-Reya15 shared
- Davide Ruggero10 shared
- Qi Wen Fan7 shared
- Kevan M. Shokat7 shared
- Livia Garzia6 shared
- Allan Balmain5 shared
- Daphne A. Haas-Kogan5 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Kyle M Walsh$4,170,256
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorIn VivoPathway InteractionsChildCellsMouse ModelSignal TransductionGeneticMycn GeneBaseGenesMalignant NeoplasmsMolecularPre-ClinicalClinical TrialsMutationNeuroblastomaNeoplastic CellMedulloblastomaGenetically Engineered MouseAutomobile DrivingInhibitor/AntagonistXenograft ProcedureProteins
Grant awards (127)
Dysregulation of the Core Binding Factor Complex Inhibits Differentiation and Drives Group 4 Medulloblastoma$706,017
R01 · FY2025 · CA
Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications$666,183
R01 · FY2025 · NS · contact PI
Brain-Restricted Kinase Inhibition with Binary Pharmacology$663,348
R01 · FY2025 · CA · contact PI
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$630,753
R01 · FY2025 · CA · contact PI
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$157,894
R01 · FY2025 · CA · contact PI
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$749,215
R01 · FY2024 · CA · contact PI
Brain-Restricted Kinase Inhibition with Binary Pharmacology$671,177
R01 · FY2024 · CA · contact PI
Dysregulation of the Core Binding Factor Complex Inhibits Differentiation and Drives Group 4 Medulloblastoma$670,714
R01 · FY2024 · CA
Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications$646,197
R01 · FY2024 · NS · contact PI
Targeting neuroblastoma cell state plasticity$624,652
P01 · FY2024 · CA · contact PI
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$772,874
R01 · FY2023 · CA · contact PI
Dysregulation of the Core Binding Factor Complex Inhibits Differentiation and Drives Group 4 Medulloblastoma$706,017
R01 · FY2023 · CA
Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications$666,183
R01 · FY2023 · NS · contact PI
Pediatric Malignancies Program$183,249
P30 · FY2023 · CA · contact PI
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$772,874
R01 · FY2022 · CA · contact PI
Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications$666,183
R01 · FY2022 · NS · contact PI
Dysregulation of the Core Binding Factor Complex Inhibits Differentiation and Drives Group 4 Medulloblastoma$643,914
R01 · FY2022 · CA
Improving the efficacy of mTOR inhibition$578,475
R01 · FY2022 · CA · contact PI
Prevention and treatment of lethal metastases in group 3 medulloblastoma$566,563
R01 · FY2022 · NS · contact PI
Project 4: Targeting 4EBP1 in glioblastoma$341,387
P50 · FY2022 · CA · contact PI
Dysregulation of the Core Binding Factor Complex Inhibits Differentiation and Drives Group 4 Medulloblastoma$159,218
R01 · FY2022 · CA
Pediatric Malignancies Program$87,279
P30 · FY2022 · CA · contact PI
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers$1,010,431
U01 · FY2021 · CA · contact PI
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma$819,398
R01 · FY2021 · CA · contact PI
Mouse models to discover new drivers of medulloblastoma$746,845
R01 · FY2021 · CA
Improving the efficacy of mTOR inhibition$590,279
R01 · FY2021 · CA · contact PI
Prevention and treatment of lethal metastases in group 3 medulloblastoma$566,614
R01 · FY2021 · NS · contact PI
Proj 2 - Exploiting Therapeutic Vulnerabilities$355,201
P01 · FY2021 · CA · contact PI
Project 4: Targeting 4EBP1 in glioblastoma$341,389
P50 · FY2021 · CA · contact PI
Pediatric Malignancies Program$122,428
P30 · FY2021 · CA · contact PI
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers$1,010,431
U01 · FY2020 · CA · contact PI
Mouse models to discover new drivers of medulloblastoma$746,845
R01 · FY2020 · CA
Improving the efficacy of mTOR inhibition$588,452
R01 · FY2020 · CA · contact PI
Prevention and treatment of lethal metastases in group 3 medulloblastoma$566,684
R01 · FY2020 · NS · contact PI
Proj 2 - Exploiting Therapeutic Vulnerabilities$386,498
P01 · FY2020 · CA · contact PI
Project 4: Targeting 4EBP1 in glioblastoma$352,500
P50 · FY2020 · CA · contact PI
Pediatric Malignancies Program$79,592
P30 · FY2020 · CA · contact PI
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers$980,118
U01 · FY2019 · CA · contact PI
Mouse models to discover new drivers of medulloblastoma$724,440
R01 · FY2019 · CA
Targeting BET-bromodomains in neuroblastoma$641,224
R01 · FY2019 · NS · contact PI
Improving the efficacy of mTOR inhibition$568,138
R01 · FY2019 · CA · contact PI
Prevention and treatment of lethal metastases in group 3 medulloblastoma$564,833
R01 · FY2019 · NS · contact PI
Precision Medicine For Pediatric Low-Grade Gliomas$520,926
R01 · FY2019 · NS
Project 4: Targeting 4EBP1 in glioblastoma$346,718
P50 · FY2019 · CA · contact PI
Exploiting Therapeutic Vulnerabilities$262,672
P01 · FY2019 · CA · contact PI
Pediatric Malignancies Program$86,716
P30 · FY2019 · CA · contact PI
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers$1,010,431
U01 · FY2018 · CA · contact PI
Mouse models to discover new drivers of medulloblastoma$746,845
R01 · FY2018 · CA
Targeting BET-bromodomains in neuroblastoma$651,177
R01 · FY2018 · NS · contact PI
MYCN, mTOR and translation control in medulloblastoma$596,770
R01 · FY2018 · NS · contact PI
Improving the efficacy of mTOR inhibition$583,883
R01 · FY2018 · CA · contact PI
Prevention and treatment of lethal metastases in group 3 medulloblastoma$578,681
R01 · FY2018 · NS · contact PI
Precision Medicine For Pediatric Low-Grade Gliomas$520,295
R01 · FY2018 · NS
Project 4: Targeting 4EBP1 in glioblastoma$366,730
P50 · FY2018 · CA · contact PI
Exploiting Therapeutic Vulnerabilities$270,796
P01 · FY2018 · CA · contact PI
Integrating targeted and immunotherapy to treat genetically heterogeneous cancers$1,065,613
U01 · FY2017 · CA · contact PI
Mouse models to discover new drivers of medulloblastoma$794,344
R01 · FY2017 · CA
Targeting BET-bromodomains in neuroblastoma$675,172
R01 · FY2017 · NS · contact PI
MYCN, mTOR and translation control in medulloblastoma$603,492
R01 · FY2017 · NS · contact PI
Precision Medicine For Pediatric Low-Grade Gliomas$520,168
R01 · FY2017 · NS
Exploiting Therapeutic Vulnerabilities$328,133
P01 · FY2017 · CA · contact PI
Targeting BET-bromodomains in neuroblastoma$669,055
R01 · FY2016 · NS · contact PI
MYCN, mTOR and translation control in medulloblastoma$614,079
R01 · FY2016 · NS · contact PI
Precision Medicine For Pediatric Low-Grade Gliomas$521,946
R01 · FY2016 · NS
Integrating mass cytometric and transcriptomic profiles of solid tumors$383,817
R33 · FY2016 · CA · contact PI
Genetic network analysis of cancer targets$308,486
U01 · FY2016 · CA · contact PI
Murine Neuroblastoma Models for Preclinical Therapeutics$261,089
R01 · FY2016 · CA · contact PI
Targeting BET-bromodomains in neuroblastoma$698,744
R01 · FY2015 · NS · contact PI
MYCN, mTOR and translation control in medulloblastoma$623,844
R01 · FY2015 · NS · contact PI
Cellular and Genetic Basis of Anaplastic Medulloblastoma$617,747
R01 · FY2015 · CA
Precision Medicine For Pediatric Low-Grade Gliomas$551,281
R01 · FY2015 · NS
Integrating mass cytometric and transcriptomic profiles of solid tumors$389,651
R33 · FY2015 · CA · contact PI
Genetic network analysis of cancer targets$308,328
U01 · FY2015 · CA · contact PI
Murine Neuroblastoma Models for Preclinical Therapeutics$261,089
R01 · FY2015 · CA · contact PI
Regulation and function of the vascular niche in glioma recurrance$57,469
U54 · FY2015 · CA · contact PI
Diversity Supplement for MYCN, mTOR and translation control in medulloblastoma$18,214
R01 · FY2015 · NS · contact PI
MYCN, mTOR and translation control in medulloblastoma$632,206
R01 · FY2014 · NS · contact PI
Cellular and Genetic Basis of Anaplastic Medulloblastoma$599,474
R01 · FY2014 · CA
Medulloblastoma and Metastases$455,065
R01 · FY2014 · CA · contact PI
Integrating mass cytometric and transcriptomic profiles of solid tumors$408,712
R33 · FY2014 · CA · contact PI
Genetic network analysis of cancer targets$303,890
U01 · FY2014 · CA · contact PI
TARGETING MYCN PROTEIN WITH SMALL MOLECULES$275,587
P01 · FY2014 · CA · contact PI
Murine Neuroblastoma Models for Preclinical Therapeutics$252,496
R01 · FY2014 · CA · contact PI
Regulation and function of the vascular niche in glioma recurrance$84,522
U54 · FY2014 · CA · contact PI
Cellular and Genetic Basis of Anaplastic Medulloblastoma$581,217
R01 · FY2013 · CA
Medulloblastoma and Metastases$442,785
R01 · FY2013 · CA · contact PI
Genetic network analysis of cancer targets$313,833
U01 · FY2013 · CA · contact PI
Mycn and Medulloblastoma$292,312
R01 · FY2013 · CA · contact PI
Murine Neuroblastoma Models for Preclinical Therapeutics$243,213
R01 · FY2013 · CA · contact PI
TARGETING MYCN PROTEIN WITH SMALL MOLECULES$195,029
P01 · FY2013 · CA · contact PI
Regulation and function of the vascular niche in glioma recurrance$84,062
U54 · FY2013 · CA · contact PI
Cellular and Genetic Basis of Anaplastic Medulloblastoma$618,678
R01 · FY2012 · CA
Medulloblastoma and Metastases$488,139
R01 · FY2012 · CA · contact PI
Modifiers of Tumor Susceptibility in Murine Neuroblastoma$331,209
R01 · FY2012 · NS · contact PI
Mycn and Medulloblastoma$310,970
R01 · FY2012 · CA · contact PI
TARGETING MYCN PROTEIN WITH SMALL MOLECULES$282,760
P01 · FY2012 · CA · contact PI
Murine Neuroblastoma Models for Preclinical Therapeutics$257,953
R01 · FY2012 · CA · contact PI
Cellular and Genetic Basis of Anaplastic Medulloblastoma$640,572
R01 · FY2011 · CA
Medulloblastoma and Metastases$506,777
R01 · FY2011 · CA · contact PI
Modifiers of Tumor Susceptibility in Murine Neuroblastoma$331,209
R01 · FY2011 · NS · contact PI
Mycn and Medulloblastoma$310,970
R01 · FY2011 · CA · contact PI
TARGETING MYCN PROTEIN WITH SMALL MOLECULES$283,648
P01 · FY2011 · CA · contact PI
Medulloblastoma and Metastases$557,223
R01 · FY2010 · CA · contact PI
Modifiers of Tumor Susceptibility in Murine Neuroblastoma$334,590
R01 · FY2010 · NS · contact PI
Mycn and Medulloblastoma$320,588
R01 · FY2010 · CA · contact PI
TARGETING MYCN PROTEIN WITH SMALL MOLECULES$292,876
P01 · FY2010 · CA · contact PI
Murine Neuroblastoma Models for Preclinical Therapeutics$261,694
R01 · FY2010 · CA · contact PI
Modifiers of Tumor Susceptibility in Murine Neuroblastoma$337,969
R01 · FY2009 · NS · contact PI
Mycn and Medulloblastoma$320,588
R01 · FY2009 · CA · contact PI
Murine Neuroblastoma Models for Preclinical Therapeutics$261,694
R01 · FY2009 · CA · contact PI
Modifiers of Tumor Susceptibility in Murine Neuroblastoma$81,731
R01 · FY2009 · NS · contact PI
Modifiers of Tumor Susceptibility in Murine Neuroblastoma$337,331
R01 · FY2008 · NS · contact PI
Murine Neuroblastoma Models for Preclinical Therapeutics$261,694
R01 · FY2008 · CA · contact PI
Modifiers of Tumor Susceptibility in Murine Neuroblastoma$35,000
R01 · FY2008 · NS · contact PI
Murine Neuroblastoma Models for Preclinical Therapeutics$260,988
R01 · FY2007 · CA · contact PI
Murine Neuroblastoma Models for Preclinical Therapeutics$267,910
R01 · FY2006 · CA · contact PI
Imaging Kinase Activity In Vivo$171,056
R21 · FY2006 · NS · contact PI
Murine neuroblastoma models for preclinical therapeutics$269,670
R01 · FY2005 · CA
Imaging Kinase Activity In Vivo$175,172
R21 · FY2005 · NS
PROTEOMIC ANALYSIS OF DIAGNOSTIC BLOOD SAMPLES FOR NEUROBLASTOMA$6,239
M01 · FY2005 · RR
Murine neuroblastoma models for preclinical therapeutics$269,670
R01 · FY2004 · CA
GENETICS OF A TRANSGENIC MOUSE MODEL FOR NEUROBLASTOMA$121,770
K02 · FY2004 · NS
Murine neuroblastoma models for preclinical therapeutics$269,670
R01 · FY2003 · CA
GENETICS OF A TRANSGENIC MOUSE MODEL FOR NEUROBLASTOMA$121,770
K02 · FY2003 · NS
GENETICS OF A TRANSGENIC MOUSE MODEL FOR NEUROBLASTOMA$121,770
K02 · FY2002 · NS
GENETICS OF A TRANSGENIC MOUSE MODEL FOR NEUROBLASTOMA$121,770
K02 · FY2001 · NS
GENETICS OF A TRANSGENIC MOUSE MODEL FOR NEUROBLASTOMA$121,770
K02 · FY2000 · NS